NCT03774784 is a clinical trial in Amyloidosis, sponsored by Alnylam Pharmaceuticals.

Who is sponsoring NCT03774784?

NCT03774784 is sponsored by Alnylam Pharmaceuticals.

What condition does NCT03774784 study?

NCT03774784 studies Amyloidosis, Leukocyte Chemotactic Factor 2 Amyloidosis.

Is NCT03774784 still recruiting?

NCT03774784 is currently terminated. Last updated 16 June 2020.

Last reviewed 2020-06-16 · How we verify

NCT03774784

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

Terminated Last updated 16 June 2020

What this trial tests

trial in Amyloidosis in 26 participants. Terminated before completion.

Timeline

29 January 2019

Primary endpoint
18 May 2020

18 May 2020

Quick facts

Lead sponsor	Alnylam Pharmaceuticals
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	26
Start date	29 January 2019
Primary completion	18 May 2020
Estimated completion	18 May 2020
Sites	31 locations across Malaysia, United Kingdom, Mexico, United States, Egypt, India

Conditions studied

Amyloidosis — all drugs for Amyloidosis →
Leukocyte Chemotactic Factor 2 Amyloidosis — all drugs for Leukocyte Chemotactic Factor 2 Amyloidosis →

Sponsor

Alnylam Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Amyloidosis or Leukocyte Chemotactic Factor 2 Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2 disease will be enrolled. Participants, who have already reached end-stage renal disease (ESRD), will provide retrospective chart review data and biological specimens at baseline only. Other participants, in addition to retrospective chart review, will be followed prospectively.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

LECT2: A pleiotropic and promising hepatokine, from bench to bedside.
Xie Y, Fan KW, Guan SX, Hu Y, et al · · 2022 · cited 15× · PMID 35656863 · DOI 10.1111/jcmm.17407

Verify or expand the search:

Other recruiting trials for Amyloidosis

Currently open trials in the same condition.

NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06974877 — Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure · Phase 1 · recruiting
NCT07081646 — A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloido · Phase 1, PHASE2 · recruiting
NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
NCT06573723 — Institutional Registry of Rare Diseases · recruiting

Other Alnylam Pharmaceuticals trials

Trials by the same sponsor.

NCT07535606 — A Study to Evaluate ALN-4915 in Adult Healthy Volunteers · Phase 1 · recruiting
NCT07463846 — A Study to Evaluate ALN-2232 in Participants With Obesity · Phase 1, PHASE2 · recruiting
NCT07223203 — TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidos · Phase 3 · recruiting
NCT07465224 — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · Phase 2 · recruiting
NCT07358078 — DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03774784 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alnylam Pharmaceuticals
Last refreshed: 16 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03774784.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing